DOCSLIB.ORG

A Acinic Cell Carcinoma, 13, 14 Actinic Keratosis, 101 Adamantinoma, 95

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Acinic Cell Carcinoma, 13, 14 Actinic Keratosis, 101 Adamantinoma, 95 Index A Adrenal tumors dysembryoplastic neuroepithelial Acinic cell carcinoma, 13, 14 ganglioneuroblastoma, 49–53 tumor (DNET), 117 Actinic keratosis, 101 ganglioneuroma, 49 embryonal tumors, 114 Adamantinoma, 95 neuroblastoma, 49–50 ependymoma, 112–113 Adenocarcinoma Anaplasia, 1 gangliocytoma, 114, 116 biliary, 44 Anemia, refractory, 87, 88, 89 ganglioglioma, 114, 116 cervical, 69 Angiosarcoma, 94, 102–104 desmoplastic infantile, 110, 111 clear cell Antibody MIB-1 (Ki-67), 3 ganglioneuroblastoma, 49, 51–53 cervical, 69 Astroblastoma, 110–111 hemangioblastoma, 121 endometrial, 71 Astrocytoma, 107–111 medulloblastoma, 114–115 ependymoma, 113 desmoplastic cerebral astrocytoma of meningioma, 117–120 meningioma, 119 infancy (DCAI), 110 neurocytoma, 114, 116 pulmonary, 27 neuroepithelial neoplasm-related, 114 neuronal tumors, 114, 116–117 of the salivary glands, 13 pineal parenchymal tumor, 115–116 thymic, 33, 34 B pineoblastoma, 114, 115, 116 colorectal, 40–42 Basal cell carcinoma, 99–100 pineocytoma, 116 endometrial, 69–71 prostatic, 60 retinoblastoma, 114 of the fallopian tubes, 72 Biliary system, adenocarcinoma of, 44 supratentorial primitive of the gallbladder, 44 Blastoma, monophasic pulmonary, 27 neuroepithelial tumor, 115 gastric, 39–40 Bone tumors. See Sarcoma, of bone Cervical intraepithelial neoplasia (CIN), ovarian, 72 Bowen disease, 101 66–68 pancreatic, 44–45 Breast carcinoma, 75–81 Cervix, adenocarcinoma of, 69 prostatic, 3, 57–59, 59, 60 ductal carcinoma in situ, 75–77 Children, soft-tissue sarcoma in, 93 pulmonary, 23, 25–27 ductal invasive, 79, 80 Cholangiocarcinoma, intrahepatic, 43–44 of the salivary glands, 13, 14, 16 histologic grading of, 1 Chondrosarcoma, 81, 94, 95–97 sinonasal, 10 immunohistochemical studies of, 3 Chordoma, 95 Adenoid cystic carcinoma invasive, 77–80 Choriocarcinoma, 72 cervical, 69 lobular carcinoma in situ, 77 Choroid plexus neoplasms, 120–121 prostatic, 60 phyllodes tumors, 80–81 Colon/colorectal carcinoma, 1, 40–42 Adenoid (pseudoglandular) squamous Broders, A. C., 1, 2, 3 Craniopharyngioma, 121–121 cell carcinoma, 102 Crohn disease, 42 Adenoma C Cystadenocarcinoma, 13 adrenocortical, 48–49 Carcinoid tumors, pulmonary, 28 Cystosarcoma phyllodes, 80 parathyroid, 48 Carcinoma ex pleomorphic adenoma, Cytopenia, refractory, 87–88 pituitary, 47 16–17 thyroid, 47 Central nervous system tumors, 107–122 D Adenosquamous carcinoma astrocytoma, 107–111 Dabska tumors, 102–103 laryngeal, 22 pilocytic, 108–110 Desmoplastic cerebral astrocytoma of of the salivary glands, 13 special variants of, 108–111 infancy (DCAI), 110 thymic, 33 central neurocytoma, 116 Desmosomes, 101 Adrenal cortical tumors, 48–49 choroid plexus neoplasms, 120–121 Digestive system tumors, 35–46 Adrenal medullary tumors, 49 craniopharyngioma, 121–121 biliary system adenocarcinoma, 44 123 124 Index Digestive system tumors (cont.) G Keratosis, 6 colorectal adenocarcinoma, 40–42 Gallbladder adenocarcinoma, 44 actinic, 101 esophageal adenocarcinoma, 36–38 Gangliocytoma, 114, 116 Ki-67 (antibody MIB-1), 3 esophageal squamous cell carcinoma, Ganglioglioma, 114, 116 35–36 desmoplastic infantile, 110, 111 L gallbladder adenocarcinoma, 44 Ganglioneuroblastoma, 49–53 Large cell carcinoma, pulmonary, 23 gastric adenocarcinoma, 39–40 Ganglioneuroma, 49 Large cell neuroendocrine carcinoma gastrointestinal stromal tumors, 39, 40 Gastrointestinal stromal tumors (GIST), (LCNEC), 27, 29 hepatocellular carcinoma, 42–43 39, 40 Laryngeal tumors, 19–22 intrahepatic cholangiocarcinoma, Genital organ tumors, in females, 64–74 Leiomyoma, 71–72 43–44 adenocarcinoma of the fallopian Leiomyosarcoma, 71, 72 pancreatic adenocarcinoma, 44–45 tubes, 72 Leukemia, acute, 89 Dysembryoplastic neuroepithelial tumor cervical adenocarcinoma, 69 Leukoplakia, 6 (DNET), 117 cervical intraepithelial neoplasia, Lip, squamous cell carcinoma of, 94 Dysgerminoma, 72 66–68 Liposarcoma, 81 Dysplasia endometrial adenocarcinoma, 69–71 Lobular carcinoma in situ, 77 colorectal, 42 germ cell tumors, 72–73 Lung carcinoma, 23–30 intraurothelial, 61 invasive squamous cell carcinoma of adenocarcinoma, 23, 25–27 squamous cervical, 66–67 the cervix, 68–69 large cell, 23 squamous oral, 6, 7 invasive squamous cell carcinoma of neuroendocrine carcinoma, 23, 27–29 squamous vulvar, 64 the vulva, 64–66 small cell sex cord stromal tumors, 73 pulmonary “oat-cell,” 53 E smooth muscle cell tumors, 71–72 squamous cell carcinoma, 25 Embryonal carcinoma, 72 vaginal tumors, 66 squamous cell, 23–25 Endocrine tumors, 47–54 vulvar squamous intraepithelial Lymphangioma, differentiated from adrenal cortical tumors, 48–49 neoplasia, 64 angiosarcoma, 103 adrenal medullary tumors, 49 Germ cell tumors, ovarian, 72–73 Lymphedema, angiosarcoma associated pancreatic islet cell tumors, 53 Giant cell carcinoma, pleomorphic, 60 with, 103 parathyroid tumors, 48 Glioblastoma, 108 Lymph nodes, involvement in mycosis peripheral neuroblastic tumors, 49–53 with oligodendroglioma component, fungoides, 85–86, 87 pituitary tumors, 47 112 Lymphoepithelial carcinoma, laryngeal, thyroid tumors, 47–48 Gliofibroma, 110–111 22 Endometrial adenocarcinoma, 69–70 Glioma, choroid, 110–111 Lymphoepithelioma-like carcinoma estrogen-related (endometroid), Gliomatosis cerebri, 110–111 pulmonary, 25 69–70 Granulosa cell tumors, 73 squamous cell endometrial, 68–69 non-estrogen-related, 71 Lymphoid system tumors. See Ependymoma, 112–113 H Lymphoma Epidermal growth factor receptor Hemangioblastoma, 121 Lymphoma (EGFR), 42 Hemangioendothelioma, 102–103 of bone, 95 Epithelial-myoepithelial carcinoma, 13 Hemangioma, differentiated from Hodgkin, 85 Epstein-Barr virus, 9 angiosarcoma, 103 non-Hodgkin, 82–87 Erythroplakia, 6 Hematopoietic system tumors, 82, follicular, 82–83 Esophageal carcinoma 87–89 mantle cell, 83–84 adenocarcinoma, 36, 38 Hemgioendothelioma, 94 mycosis fungoides, 85–87 squamous cell carcinoma, 35, 36 Hepatocellular carcinoma, 42–43 Esophagus, Barrett, 36–38 Homer-Wright rosettes, 10, 114 M Human papilloma virus (HPV), 64, 68 Macroadenoma, pituitary, 47 F Hyperplasia Malignant fibrous histiocytoma (MFH), Fallopian tubes, adenocarcinoma of, 72 laryngeal, 19, 20 94 Familial atypical mole and melanoma urothelial, 60 Malignant mixed tumors, of the salivary syndrome, 105 glands, 16–17 Fibroepithelioma, of Pinkus, 100 I Mastectomy, as angiosarcoma risk Fibroma, ovarian, 73 Intraductal papillary-mucinous factor, 103 Fibrosarcoma, 94 neoplasm (IPMN), 45 Medullary carcinoma, thyroid, 47, 48 differentiated from angiosarcoma, 103 Islet cell tumors, pancreatic, 53 Medulloblastoma, 114–115 phyllodes tumor-related, 81 Melanoma 5q-syndrome, 87, 88, 89 K differentiated from angiosarcoma, 103 Flexner-Wintersteiner rosettes, 10 Keratoacanthoma, 102 dysplastic nevus-related, 105 Foamy gland carcinoma, 59 Keratoacanthoma-like squamous cell Meningioma, 117–120 Follicular carcinoma, thyroid, 47, 48 carcinoma, 66 atypical, 119 Index 125 benign, 117–118 Parakeratosis, 101 Small cell tumors malignant or anaplastic, 120 Parathyroid tumors, 48 endometrial adenocarcinoma, 71 Mesothelioma, malignant, 29–30 Peripheral neuroblastic tumors, 49–53 islet cell, 53 Metastases, grading of, 3 p53, 3 neuroendocrine carcinoma (SCNEC), Microadenoma, pituitary, 47 Pheochromocytoma, 49 27, 29 Microcalcification, breast carcinoma- Phyllodes tumors, 80–81 neuroendocrine thymic carcinoma, 33 related, 77 Pineal parenchymal tumors, 115–116 pulmonary “oat-cell,” 53 Mouth, squamous cell carcinoma of, Pineoblastoma, 114, 115, 116 pulmonary squamous cell carcinoma, 6–8 Pineocytoma, 116 25 Mucoepidermoid carcinoma Pinkus, fibroepithelioma of, 100 Smooth muscle cell tumors, uterine, of the salivary glands, 13–15 Pituitary tumors, 47 71–72 thymic, 33 Pleomorphic giant cell carcinoma, 60 Spindle cell carcinoma Musculoskeletal system tumors, 91–98 Primitive neuroectodermal tumors gastrointestinal stromal tumors bone sarcoma, 94–97 (PNETs), 114 (GIST), 40 soft-tissue sarcoma, 91–94 Primitive neuroepithelial tumors, hepatocellular, 42 Mycosis fungoides, 85–87 supratentorial, 115 laryngeal, 22 Myelodysplastic syndromes, 87–89 Prognostic markers, for cancer, 3 mesothelioma, 29 with isolated del(5q) chromosome Prostate carcinoma, 3, 55, 57–60 squamous cell, 25, 102 abnormalities, 87, 88, 89 number of grading systems for, 1 Squamous cell carcinoma Myeloma, 95 variant forms of, 59–60 cervical invasive, 68–69 Myxofibrosarcoma, 92, 93 Pseudopsammoma bodies, 118, 119 cutaneous, 100–102 of the lip, 94 N R esophageal, 35, 36 Nasopharyngeal carcinoma, 8–9 Radiation therapy, as angiosarcoma laryngeal and hyopharyngeal, 19, 20, Neuroblastic tumors, peripheral, cause, 103 21, 22 49–53 Renal cell carcinoma, 55–56 nasopharyngeal, 8–9 schwannian stroma-poor, 49–50, 51 Retinoblastoma, 114 oral, 6–8 schwannian stroma-rich, 50–53 Rhabdomyosarcoma, 81 pulmonary, 23–25 Neuroblastoma of the salivary glands, 13 adrenal, 49–50 S sinonasal, 9 cerebellar, 114 Salivary duct carcinoma, 13 spindle cell, 25, 102 olfactory, 6, 10–11 Salivary gland tumors, 13–19 thymic, 33 Neurocytoma, 114, 116 adenocarcinoma, 13, 15–16 vaginal, 66 central, 116 adenoid cystic carcinoma, 13, 16, 17 vulvar, 64–66 Neuroendocrine tumors, 9 high-grade malignant, 13 Squamous epithelial lesions (SILs), prostatic, 59–60 low-grade malignant, 13, 14 19–21 pulmonary, 23, 27–29 malignant mixed tumors, 13, 16–17 Stomach, adenocarcinoma of, 39–40 Neuronal tumors, 114, 116–117 mucoepidermoid carcinoma, 13–15 STUMPs (smooth muscle tumor Nevus, dysplastic, 104–105 Sarcoglioma, 110–111 of uncertain malignant Sarcoma potential), 71, 72 O of bone, 94–97
Load more

Recommended publications
  • Acinic Cell Carcinoma with Extensive Neuroendocrine Differentiation: a Diagnostic Challenge
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central Head and Neck Pathol (2009) 3:163–168 DOI 10.1007/s12105-009-0114-5 CASE REPORT Acinic Cell Carcinoma with Extensive Neuroendocrine Differentiation: A Diagnostic Challenge Somak Roy Æ Kajal Kiran Dhingra Æ Parul Gupta Æ Nita Khurana Æ Bulbul Gupta Æ Ravi Meher Received: 30 January 2009 / Accepted: 11 March 2009 / Published online: 26 March 2009 Ó Humana 2009 Abstract Primary salivary gland carcinoma with neuro- Keywords Neuroendocrine Á Acinic cell Á Warthin’s Á endocrine differentiation is of rare occurrence, especially Chromogranin Á Carcinoma Á Parotid so in the parotid gland. Amongst the various reported pri- mary tumors with neuroendocrine differentiation, acinic cell carcinoma (ACC) one such tumor. A 48 year old lady Introduction presented with a gradually increasing right infra-auricular swelling for a period of 1 year which enlarged suddenly in Primary salivary gland carcinomas with neuroendocrine a short period. Contrast Enhanced Computed Tomography differentiation are rare accounting for 3.5% of all malig- (CECT) suggested diagnosis of Pleomorphic Adenoma. nant tumors and less than 1% of all carcinomas of parotid Fine Needle Aspiration Cytology (FANC) yielded a cystic gland [1]. Nicod reported the first case of carcinoid tumor fluid suggesting a possibility of Warthin’s tumor or of the parotid gland in a 51 year old lady [2]. Following Oncocytic lesion. Intraoperative findings were suggestive this there have been occasional reports of round cell tumors of a Warthin’s tumor. Initial histopathological examination of the parotid gland and minor salivary glands with very of the tumor was suggestive of neuroendocrine carcinoma.
    [Show full text]
  • Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart
    Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Glial Tumor Neuronal and Neuronal‐ Ependymomas glial Neoplasms Subependymoma Subependymal Giant (9383/1) Cell Astrocytoma(9384/1) Myyppxopapillar y Desmoplastic Infantile Ependymoma Astrocytoma (9412/1) (9394/1) Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Glial Tumor Neuronal and Neuronal‐ Ependymomas glial Neoplasms Subependymoma Subependymal Giant (9383/1) Cell Astrocytoma(9384/1) Myyppxopapillar y Desmoplastic Infantile Ependymoma Astrocytoma (9412/1) (9394/1) Use this chart to code histology. The tree is arranged Chart Instructions: Neuroepithelial in descending order. Each branch is a histology group, starting at the top (9503) with the least specific terms and descending into more specific terms. Ependymal Embryonal Pineal Choro id plexus Neuronal and mixed Neuroblastic Glial Oligodendroglial tumors tumors tumors tumors neuronal-glial tumors tumors tumors tumors Pineoblastoma Ependymoma, Choroid plexus Olfactory neuroblastoma Oligodendroglioma NOS (9391) (9362) carcinoma Ganglioglioma, anaplastic (9522) NOS (9450) Oligodendroglioma (9390) (9505 Olfactory neurocytoma Ganglioglioma, malignant (()9521) anaplastic (()9451) Anasplastic ependymoma (9505) Olfactory neuroepithlioma Oligodendroblastoma (9392) (9523) (9460) Papillary ependymoma (9393) Glioma, NOS (9380) Supratentorial primitive Atypical EdEpendymo bltblastoma MdllMedulloep ithliithelioma Medulloblastoma neuroectodermal tumor tetratoid/rhabdoid (9392) (9501) (9470) (PNET) (9473) tumor
    [Show full text]
  • Adrenal Neuroblastoma Mimicking Pheochromocytoma in an Adult With
    Khalayleh et al. Int Arch Endocrinol Clin Res 2017, 3:008 Volume 3 | Issue 1 International Archives of Endocrinology Clinical Research Case Report : Open Access Adrenal Neuroblastoma Mimicking Pheochromocytoma in an Adult with Neurofibromatosis Type 1 Harbi Khalayleh1, Hilla Knobler2, Vitaly Medvedovsky2, Edit Feldberg3, Judith Diment3, Lena Pinkas4, Guennadi Kouniavsky1 and Taiba Zornitzki2* 1Department of Surgery, Hebrew University Medical School of Jerusalem, Israel 2Endocrinology, Diabetes and Metabolism Institute, Kaplan Medical Center, Hebrew University Medical School of Jerusalem, Israel 3Pathology Institute, Kaplan Medical Center, Israel 4Nuclear Medicine Institute, Kaplan Medical Center, Israel *Corresponding author: Taiba Zornitzki, MD, Endocrinology, Diabetes and Metabolism Institute, Kaplan Medical Center, Hebrew University Medical School of Jerusalem, Bilu 1, 76100 Rehovot, Israel, Tel: +972-894- 41315, Fax: +972-8 944-1912, E-mail: [email protected] Context 2. This is the first reported case of an adrenal neuroblastoma occurring in an adult patient with NF1 presenting as a large Neurofibromatosis type 1 (NF1) is a genetic disorder asso- adrenal mass with increased catecholamine levels mimicking ciated with an increased risk of malignant disorders. Adrenal a pheochromocytoma. neuroblastoma is considered an extremely rare tumor in adults and was not previously described in association with NF1. 3. This case demonstrates the clinical overlap between pheo- Case description: A 42-year-old normotensive woman with chromocytoma and neuroblastoma. typical signs of NF1 underwent evaluation for abdominal pain, Keywords and a large 14 × 10 × 16 cm left adrenal mass displacing the Adrenal neuroblastoma, Neurofibromatosis type 1, Pheo- spleen, pancreas and colon was found. An initial diagnosis of chromocytoma, Neural crest-derived tumors pheochromocytoma was done based on the known strong association between pheochromocytoma, NF1 and increased catecholamine levels.
    [Show full text]
  • Report of a Case of Acinic Cell Carcinoma of the Upper Lip and Review of Japanese Cases of Acinic Cell Carcinoma of the Minor Salivary Glands
    J Clin Exp Dent-AHEAD OF PRINT Acinic cell carcinoma of the minor salivary glands Journal section: Oral Surgery doi:10.4317/jced.53049 Publication Types: Case Report http://dx.doi.org/10.4317/jced.53049 Report of a case of acinic cell carcinoma of the upper lip and review of Japanese cases of acinic cell carcinoma of the minor salivary glands Shigeo Ishikawa 1, Hitoshi Ishikawa 2, Shigemi Fuyama 3, Takehito Kobayashi 4, Takayoshi Waki 5, Yukio Taira 4, Mitsuyoshi Iino 1 1 Department of Dentistry, Oral and Maxillofacial Plastic and Reconstructive Surgery, Faculty of Medicine, Yamagata University, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan 2 Yamagata Saisei Hospital, Department of Health Information Management, 79-1 Oki-machi, Yamagata 990-8545, Japan 3 Department of Diagnostic Pathology, Okitama Public General Hospital, 2000 Nishi-Otsuka, Kawanishi, Higashi-Okitama-gun, Yamagata 992-0601, Japan 4 Department of Dentistry, Oral and Maxillofacial Surgery, Okitama Public General Hospital, 2000 Nishi-Otsuka, Kawanishi, Higashi-Okitama-gun, Yamagata 992-0601, Japan 5 Department of Otolaryngology and Head and Neck Surgery, Okitama Public General Hospital, 2000 Nishi-Otsuka, Kawanishi, Higashi-Okitama-gun, Yamagata 992-0601, Japan Correspondence: Department of Dentistry, Oral and Maxillofacial Plastic and Reconstructive Surgery Faculty of Medicine, Yamagata University 2-2-2 Iida-nishi, Yamagata 990-9585, Japan [email protected] Please cite this article in press as: Ishikawa S, Ishikawa H, Fuyama S, Received: 17/02/2016 Kobayashi T, Waki T, Taira Y, Iino M. ������������������������������������Report of a case of acinic cell car- Accepted: 15/04/2016 cinoma of the upper lip and review of japanese cases of acinic cell carci- noma of the minor salivary glands.
    [Show full text]
  • Evaluation of PAX2 and PAX8 Expression in Salivary Gland Neoplasms
    Head and Neck Pathol (2015) 9:47–50 DOI 10.1007/s12105-014-0546-4 ORIGINAL PAPER Evaluation of PAX2 and PAX8 Expression in Salivary Gland Neoplasms Randall T. Butler • Megan A. Alderman • Lester D. R. Thompson • Jonathan B. McHugh Received: 3 March 2014 / Accepted: 16 April 2014 / Published online: 26 April 2014 Ó Springer Science+Business Media New York 2014 Abstract PAX2 and PAX8 are transcription factors Introduction involved in embryogenesis that have been utilized as immunohistochemical indicators of tumor origin. Specifi- The PAX genes encode a family of nine transcription fac- cally, PAX2 is a marker of neoplasms of renal and tors, defined by the presence of a 128-amino acid DNA- mu¨llerian origin, while PAX8 is expressed by renal, binding sequence called the ‘‘paired domain,’’ that have mu¨llerian, and thyroid tumors. While studies examining been shown to play integral roles in development and these transcription factors in a variety of tumors have been maintenance of pluripotent stem cells [1]. PAX2 and PAX8 published, data regarding their expression in salivary gland are members of the same subfamily and are involved in neoplasms are limited. The goal of this study was to assess organogenesis of the central nervous, genitourinary, and expression of PAX2 and PAX8 in a large cohort of salivary mu¨llerian systems, with PAX8 additionally involved in gland tumors. Utilizing tissue microarrays, samples of development of the thyroid gland [1]. Correspondingly, normal salivary glands (n = 68) and benign and malignant immunohistochemical detection of PAX2 and/or PAX8 salivary gland neoplasms (n = 442) were evaluated for expression has emerged as an important diagnostic tool in nuclear immunoreactivity with PAX2 and PAX8.
    [Show full text]
  • Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma Or Ependymoma (Sjyc07)
    SJCRH SJYC07 CTG# - NCT00602667 Initial version, dated: 7/25/2007, Resubmitted to CPSRMC 9/24/2007 and 10/6/2007 (IRB Approved: 11/09/2007) Activation Date: 11/27/2007 Amendment 1.0 dated January 23, 2008, submitted to CPSRMC: January 23, 2008, IRB Approval: March 10, 2008 Amendment 2.0 dated April 16, 2008, submitted to CPSRMC: April 16, 2008, (IRB Approval: May 13, 2008) Revision 2.1 dated April 29, 2009 (IRB Approved: April 30, 2009 ) Amendment 3.0 dated June 22, 2009, submitted to CPSRMC: June 22, 2009 (IRB Approved: July 14, 2009) Activated: August 11, 2009 Amendment 4.0 dated March 01, 2010 (IRB Approved: April 20, 2010) Activated: May 3, 2010 Amendment 5.0 dated July 19, 2010 (IRB Approved: Sept 17, 2010) Activated: September 24, 2010 Amendment 6.0 dated August 27, 2012 (IRB approved: September 24, 2012) Activated: October 18, 2012 Amendment 7.0 dated February 22, 2013 (IRB approved: March 13, 2013) Activated: April 4, 2013 Amendment 8.0 dated March 20, 2014. Resubmitted to IRB May 20, 2014 (IRB approved: May 22, 2014) Activated: May 30, 2014 Amendment 9.0 dated August 26, 2014. (IRB approved: October 14, 2014) Activated: November 4, 2014 Un-numbered revision dated March 22, 2018. (IRB approved: March 27, 2018) Un-numbered revision dated October 22, 2018 (IRB approved: 10-24-2018) RISK-ADAPTED THERAPY FOR YOUNG CHILDREN WITH EMBRYONAL BRAIN TUMORS, HIGH-GRADE GLIOMA, CHOROID PLEXUS CARCINOMA OR EPENDYMOMA (SJYC07) Principal Investigator Amar Gajjar, M.D. Division of Neuro-Oncology Department of Oncology Section Coordinators David Ellison, M.D., Ph.D.
    [Show full text]
  • Malignant CNS Solid Tumor Rules
    Malignant CNS and Peripheral Nerves Equivalent Terms and Definitions C470-C479, C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753 (Excludes lymphoma and leukemia M9590 – M9992 and Kaposi sarcoma M9140) Introduction Note 1: This section includes the following primary sites: Peripheral nerves C470-C479; cerebral meninges C700; spinal meninges C701; meninges NOS C709; brain C710-C719; spinal cord C720; cauda equina C721; olfactory nerve C722; optic nerve C723; acoustic nerve C724; cranial nerve NOS C725; overlapping lesion of brain and central nervous system C728; nervous system NOS C729; pituitary gland C751; craniopharyngeal duct C752; pineal gland C753. Note 2: Non-malignant intracranial and CNS tumors have a separate set of rules. Note 3: 2007 MPH Rules and 2018 Solid Tumor Rules are used based on date of diagnosis. • Tumors diagnosed 01/01/2007 through 12/31/2017: Use 2007 MPH Rules • Tumors diagnosed 01/01/2018 and later: Use 2018 Solid Tumor Rules • The original tumor diagnosed before 1/1/2018 and a subsequent tumor diagnosed 1/1/2018 or later in the same primary site: Use the 2018 Solid Tumor Rules. Note 4: There must be a histologic, cytologic, radiographic, or clinical diagnosis of a malignant neoplasm /3. Note 5: Tumors from a number of primary sites metastasize to the brain. Do not use these rules for tumors described as metastases; report metastatic tumors using the rules for that primary site. Note 6: Pilocytic astrocytoma/juvenile pilocytic astrocytoma is reportable in North America as a malignant neoplasm 9421/3. • See the Non-malignant CNS Rules when the primary site is optic nerve and the diagnosis is either optic glioma or pilocytic astrocytoma.
    [Show full text]
  • Acinic Cell Carcinoma of the Salivary Gland: a Continuing Medical Education Case Diane A
    CME/MOC Section Editor: Daniel F. I. Kurtycz, M.D. Jointly sponsored by the University of Wisconsin School Authors: Robert T. Pu, M.D., Ph.D., Assistant Professor, of Medicine and Public Health, Office of Continuing Pro- Co-Director, UM Cancer Center Tissue Core, Department of fessional Development in Medicine and Public Health and Pathology, The University of Michigan Medical School, the Wisconsin State Laboratory of Hygiene. Ann Arbor, Michigan; Diane A. Hall, M.D., Ph.D., Surgical Statement of Need: To reinforce the diagnostic features Pathology Fellow, Department of Pathology, The University of medullary carcinoma and to reacquaint the reader with of Michigan, Ann Arbor, Michingan. the clinical laboratory tests needed to support this diagnosis. Educational Reviewer: Daniel F. I. Kurtycz, M.D., Pro- Target Audience: Cytopathologists, cytopathology fel- fessor, Department of Pathology and Laboratory Medicine, lows, and other healthcare professionals. Wisconsin School of Medicine and Public Health, Medical Learning Objectives: After completing this exercise, Director, Wisconsin State Laboratory of Hygiene. participants should be able to: Disclosure of Faculty Relationships: As a sponsor accredited by the ACCME, it is the policy of the University 1. Identify the general features of medullary carcinoma of Wisconsin School of Medicine and Public Health to of the thyroid. require the disclosure of the existence of any significant fi- 2. Describe the cytologic morphology of medullary nancial interest or any other relationship a faculty member carcinoma of the thyroid derived from Fine Needle or a sponsor has with either the commercial supporter(s) of Aspiration samples. this activity or the manufacturer(s) of any commercial 3.
    [Show full text]
  • Acinic Cell Carcinoma of the Palatine Tonsil - a Brief Case Report
    The Korean Journal of Pathology 2010; 44: 441-3 DOI: 10.4132/KoreanJPathol.2010.44.4.441 Acinic Cell Carcinoma of the Palatine Tonsil - A Brief Case Report - Hun-Soo Kim∙Keum Ha Choi Acinic cell carcinoma (ACC) is a rare, low-grade malignancy of the salivary glands. Most cases occur in the major salivary glands, especially the parotid gland, with only a few cases involving Department of Pathology, Wonkwang the minor salivary gland previously described. A 67-year-old male patient was admitted com- University School of Medicine, Iksan, plaining of an obstructive feeling in the throat. On examination, a lobulated mass in the tonsil- Korea lar surface was noticed. Tonsillectomy was performed under general anesthesia. Histopatho- logical examination of the mass revealed sheets of large, polygonal acinar cells with granu- Received : April 13, 2009 lar, slightly basophilic cytoplasm, which led to the diagnosis of ACC. Here, we present a case Accepted : September 10, 2009 of low-grade ACC of the palatine tonsil, which we believe to be the first reported case of ACC in this location. Corresponding Author Hun-Soo Kim, M.D. Department of Pathology, Wonkwang University School of Medicine, 344-2 Sinyong-dong, Iksan 570-711, Korea Tel: 82-63-859-1813 Fax: 82-63-852-2110 E-mail: [email protected] *This paper was supported by Wonkwang University Key Words : Carcinoma, acinar cell; Palatine tonsil; Salivary glands, minor; Tonsillectomy; in 2008. Secretory vesicles Acinic cell carcinoma (ACC) is a relatively rare, malignant the left palatine tonsil, measuring 2.5 × 1.5 cm in size (Fig.1 epithelial neoplasm in which the tumor cells exhibit acinar inset).
    [Show full text]
  • Water-Clear Cell Adenoma of Parathyroid Gland: a Case Report and Concerns on Differential Diagnosis
    Central Journal of Endocrinology, Diabetes & Obesity Bringing Excellence in Open Access Case Report *Corresponding author Provatas Ioannis, Department of Pathology, “Evangelismos” Athens General Hospital, Ypsilantou Water-Clear Cell Adenoma of 45-47, 10676 Athens, Greece; Tel: 30-693-661-1496; Fax: 30-213-204-3128; E-mail: Parathyroid Gland: A Case Report Submitted: 06 November 2018 Accepted: 12 December 2018 and Concerns on Differential Published: 13 December 2018 ISSN: 2333-6692 Copyright Diagnosis © 2018 Ioannis et al. Provatas Ioannis1*, PandelakosStavros1, Koufopoulos Nektarios2, OPEN ACCESS Stamou Chrysa1, PavlouKalliopi1, and Helen Trihia3 Keywords 1Department of Pathology, “Evangelismos”General Hospital, Athens,Greece • Water-Clear Cell Adenoma; Parathyroid glands; 2Department of Pathology,“SaintSavvas”Anticancer Oncologic Hospital, Athens, Greece Parathormone 3Department of Pathology, “Metaxa” Cancer Hospital, Piraeus, Greece Abstract Primary Water-Clear Cell Adenoma (WCCA) of the parathyroid glands are extremely rare neoplasm, consisting of cells with clear, foamy cytoplasm filled with glycogen, lacking an infiltrative growth pattern and metastases. We report the case of a 58-year-old woman with primary hyperparathyroidism, without a known history of MEN-1 or NF-1, with a tumour posterior to the right thyroid lobe. No evidence of metastasis was reported. The clinical diagnosis was parathyroid adenoma. Following the surgical procedure, we received an encapsulated tumor measuring 4,5 cm in diameter and weighting 12 gr, consisting of water-clear cell cells, without mitoses, atypical features or capsular invasion, at the rim of which normal residual parathyroid tissue was included. The differential diagnosis included a variety of primary and secondary clear-cell tumors of head and neck region, however the morphological and immunohistochemical (strong positivity only for PTH, p27 and bcl-2) assessment drove to the diagnosis of WCCA of the parathyroid gland.
    [Show full text]
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
    [Show full text]
  • Cdx2 Protein Expression in Normal and Malignant Human Tissues: an Immunohistochemical Survey Using Tissue Microarrays Christopher A
    Cdx2 Protein Expression in Normal and Malignant Human Tissues: An Immunohistochemical Survey Using Tissue Microarrays Christopher A. Moskaluk, M.D., Ph.D., Hong Zhang, M.D., Steven M. Powell, M.D., Lisa A. Cerilli, M.D., Garret M. Hampton, Ph.D., Henry F. Frierson, Jr., M.D. Departments of Pathology (CAM, LAC, HFF), of Biochemistry and Molecular Genetics (CAM), and of Medicine (SMP), University of Virginia Health System, Charlottesville, Virginia; Department of Pathology (HZ), Anhui Medical University, Hefei, China; and Genomics Institute of the Novartis Research Foundation (GMH), San Diego, California KEY WORDS: Cdx2, immunohistochemistry, RNA Cdx2 has been identified as a marker of colon can- profiling, Tissue microarray. cer in RNA-profiling experiments. We show here Mod Pathol 2003;16(9):913–919 that the detection of Cdx2 protein by immunohis- tochemistry correlates well with RNA transcript lev- Cdx2 is a homeobox gene that has been shown to els as detected by oligonucleotide microarrays. Us- play a role in the development of the small and ing tissue microarrays containing most normal large intestine in mammals and in the differentia- tissue types and an antibody to the Cdx2 protein, tion of intestinal epithelial cells. The Cdx2 gene is strong diffuse Cdx2 staining was only seen in the expressed in all but the most distal portions of the nuclei of small and large intestinal epithelium and intestinal tract during development (1, 2). In a cell portions of the pancreatic duct system. In tissue culture model, Cdx2 has been shown to decrease microarrays containing 745 cancers from many an- cellular replication and induce differentiation to atomic sites, colonic adenocarcinomas showed mature intestinal epithelium (3).
    [Show full text]